Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Fiji

Fiji

The projected revenue for the Other Vaccines market in Fiji is expected to reach US$0.82m in 2024.
This revenue is projected to grow at an annual growth rate of 10.32% from 2024 to 2029, resulting in a market volume of US$1.34m by 2029.
In global comparison, United States is expected to generate the highest revenue in this market, amounting to US$24,730.00m in 2024.
Fiji has witnessed a growing demand for other vaccines, as the government focuses on improving public health and immunization programs.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Fiji has been experiencing growth in recent years.

Customer preferences: Fijians have become increasingly aware of the importance of vaccination in preventing diseases. With the rise of social media and access to information, Fijians are more informed about the benefits of vaccination and are taking steps to protect themselves and their families.

Trends in the market: One of the trends in the Other Vaccines market in Fiji is the increase in demand for vaccines that protect against diseases such as hepatitis A and B, meningitis, and typhoid. This is due to the growing number of Fijians who are traveling overseas for work or leisure. Another trend is the shift towards combination vaccines, which offer protection against multiple diseases in a single shot.

Local special circumstances: Fiji is a popular tourist destination, with over 840,000 visitors in 2019. This has contributed to the demand for vaccines that protect against diseases that are prevalent in other parts of the world. Additionally, Fiji has a high prevalence of certain diseases such as dengue fever, which has led to an increase in demand for vaccines that protect against it.

Underlying macroeconomic factors: The Fijian government has made significant investments in the healthcare sector in recent years, which has led to improvements in healthcare infrastructure and services. This has contributed to the growth of the Other Vaccines market in Fiji, as more Fijians have access to healthcare services and are able to afford vaccines. Additionally, the Fijian economy has been growing steadily, which has led to an increase in disposable income and a greater willingness to spend on healthcare.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.